Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Vir Biotechnology Inc (NASDAQ: VIR) closed the day trading at $4.94 down -1.98% from the previous closing price of $5.04. In other words, the price has decreased by -$1.98 from its previous closing price. On the day, 1.67 million shares were traded. VIR stock price reached its highest trading level at $5.11 during the session, while it also had its lowest trading level at $4.86.
Ratios:
For a better understanding of VIR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 7.01. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
On January 29, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $23 to $9. BofA Securities Downgraded its Buy to Neutral on September 08, 2023, whereas the target price for the stock was revised from $23 to $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when SATO VICKI L sold 22,000 shares for $4.99 per share. The transaction valued at 109,699 led to the insider holds 1,276,391 shares of the business.
Eisner Mark sold 6,796 shares of VIR for $37,162 on Jul 15 ’25. The EVP and Chief Medical Officer now owns 108,204 shares after completing the transaction at $5.47 per share. On Jul 17 ’25, another insider, Eisner Mark, who serves as the EVP and Chief Medical Officer of the company, sold 3,586 shares for $5.47 each. As a result, the insider received 19,629 and left with 104,618 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 686245056 and an Enterprise Value of 182458144. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.12 while its Price-to-Book (P/B) ratio in mrq is 0.72. Its current Enterprise Value per Revenue stands at 9.603 whereas that against EBITDA is -0.329.
Stock Price History:
The Beta on a monthly basis for VIR is 1.28, which has changed by -0.36503857 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is -2.86%, while the 200-Day Moving Average is calculated to be -27.18%.
Shares Statistics:
Over the past 3-months, VIR traded about 1.29M shares per day on average, while over the past 10 days, VIR traded about 1860450 shares per day. A total of 138.89M shares are outstanding, with a floating share count of 89.57M. Insiders hold about 35.52% of the company’s shares, while institutions hold 57.18% stake in the company. Shares short for VIR as of 1755216000 were 11487884 with a Short Ratio of 8.93, compared to 1752537600 on 11294318. Therefore, it implies a Short% of Shares Outstanding of 11487884 and a Short% of Float of 13.33.
Earnings Estimates
Vir Biotechnology Inc (VIR) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.59 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$2.87 and -$3.84 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$2.88, with 8.0 analysts recommending between -$2.4 and -$3.54.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $2.2M. There is a high estimate of $3.9M for the next quarter, whereas the lowest estimate is $500k.
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $37M, while the lowest revenue estimate was $4.7M, resulting in an average revenue estimate of $12.07M. In the same quarter a year ago, actual revenue was $74.2MBased on 8 analysts’ estimates, the company’s revenue will be $13.38M in the next fiscal year. The high estimate is $29.65M and the low estimate is $3M.
